Royal DSM injects delivery tech into scar-reduction alliance

In an expansion of its growing body of work in drug delivery, Dutch materials giant Royal DSM has struck a deal with AdeTherapeutics to advance development of treatments for pain management and scar reduction after spinal and head surgeries, the companies said. No financial terms were disclosed in DSM's release on Tuesday.

For its part, DSM is expected to add its drug-delivery know-how to the pact. AdeTherapeutics brings knowledge of developing therapeutic products, and the combination of the two companies' expertise could lead to the first treatment for scar tissue formation--known as epidural fibrosis--that can occur after spinal procedures. Scar tissue buildups can doom back surgeries, of which there are more than 1 million performed in the U.S. each year, according to DSM's release.

"This is another important step in building our presence in drug delivery and furthering DSM's ambitions in biomedical materials," stated Donato DiBiase, business director, drug delivery at DSM Biomedical. "Being active in both materials sciences and life sciences, DSM is in a unique position to create new, innovative products that address societal needs.

DSM's recent drug-delivery deals include a pact to supply drug carrier materials for a drug-eluting stent system, and the €9 billion company has been known for years as a provider of APIs for the pharmaceutical industry.

- here's the release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.